GSC line | Tumor location | Primary (P) Recurrent (R) | Overall survival (months) | EGFRvIII |
---|---|---|---|---|
#1 | Temporal | P | 12,5 | Neg |
#30 | Frontal | P | 7,5 | Pos |
#61 | Occipital | P | 6,0 | Pos |
#62 | Frontal | R | 14,0 | Neg |
#74 | Frontal | P | 8,0 | Pos |
#76 | Frontal | P | 42,0 | Neg |
#83 | Temporal | P | 8,0 | Pos |
#120 | Parietal | R | 16,5 | Neg |
#144 | Temporal | P | 26,0 | Pos |
#148 | Parietal | R | 8,0 | Neg |
#163 | Parietal | P | 2,0 | Neg |
#169 | Temporal | P | 9,0 | Neg |
#171 | Frontal | R | 17,0 | Pos |
#181 | Occipital | R | 17,0 | Pos |
#206 | Temporal | P | 27,0 | Neg |
#208 | Temporal | R | 33,0 | Neg |
#210 | Parietal | P | 10,5 | Pos |
#213 | Frontal | R | 10,5 | Neg |